Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
67
Language
English
Published on
30/10/24
You may also be interested by these reports :
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...
01/09/26
We have resumed our coverage of the Tecan Group, updating the company’s accounts and our forecasts. The share price has gained strong momentum since ...
01/09/26
Dräger’s final Q2 26 results confirmed margin acceleration across both divisions, alongside a sharp improvement in FCF and net debt. The key ...